» Articles » PMID: 30815467

Drivers of Year-to-year Variation in Exacerbation Frequency of COPD: Analysis of the AERIS Cohort

Abstract

The association between exacerbation aetiology and exacerbation frequency is poorly understood. We analysed 2-year follow-up data from a prospective observational study of patients with chronic obstructive pulmonary disease (COPD) (www.clinicaltrials.gov identifier number NCT01360398) to evaluate year-to-year variation in exacerbation frequency and related aetiology. A total of 127 patients underwent blood and sputum sampling monthly and at exacerbation to detect respiratory infections and eosinophilic inflammation; 103 continued into year 2 and 88 completed both years. The most common bacterial species at stable state and exacerbation was . Among infrequent exacerbators (one exacerbation per year), the incidence of viral infection at exacerbation was high (60.0% (95% CI 35.1-81.7%) in year 1 and 78.6% (53.4-94.2%) in year 2). Those with more frequent exacerbations tended to have higher relative incidence of bacterial than viral infection. Patients with at least two additional exacerbations in year 2 year 1 had a higher risk of colonisation at stable state than those with at least two fewer exacerbations, as detected by culture (OR 1.43 (95% CI 0.71-2.91) 0.63 (0.40-1.01), p=0.06) and PCR (1.76 (95% CI 0.88-3.51) 0.56 (0.37-0.86), p<0.01). This was not seen with other infection types or eosinophilic inflammation. Analysis of the same cohort over 2 years showed, for the first time, that changes in yearly COPD exacerbation rate may be associated with variations in colonisation.

Citing Articles

An integrative network-based approach to identify driving gene communities in chronic obstructive pulmonary disease.

Marino R, El Aalamat Y, Bol V, Caselle M, Del Giudice G, Lambert C NPJ Syst Biol Appl. 2024; 10(1):125.

PMID: 39461973 PMC: 11513021. DOI: 10.1038/s41540-024-00425-6.


Serum Immunoglobulin G Levels Are Associated with Risk for Exacerbations: An Analysis of SPIROMICS.

Burnim M, Putcha N, LaFon D, Woo H, Azar A, Groenke L Am J Respir Crit Care Med. 2024; 211(2):215-221.

PMID: 39441116 PMC: 11812537. DOI: 10.1164/rccm.202311-2184OC.


Endotyping Chronic Respiratory Diseases: T2 Inflammation in the United Airways Model.

Ambrosino P, Marcuccio G, Raffio G, Formisano R, Candia C, Manzo F Life (Basel). 2024; 14(7).

PMID: 39063652 PMC: 11278432. DOI: 10.3390/life14070899.


Lung mucosal immunity to NTHi vaccine antigens: Antibodies in sputum of chronic obstructive pulmonary disease patients.

Baffetta F, Buonsanti C, Moraschini L, Aprea S, Cane M, Lombardi S Hum Vaccin Immunother. 2024; 20(1):2343544.

PMID: 38655676 PMC: 11057560. DOI: 10.1080/21645515.2024.2343544.


A predictive model for frequent exacerbator phenotype of acute exacerbations of chronic obstructive pulmonary disease.

Zhang Y, Zheng S, Hou Y, Jie X, Wang D, Da H J Thorac Dis. 2024; 15(12):6502-6514.

PMID: 38249857 PMC: 10797373. DOI: 10.21037/jtd-23-931.


References
1.
Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

2.
Staples K, Taylor S, Thomas S, Leung S, Cox K, Pascal T . Relationships between Mucosal Antibodies, Non-Typeable Haemophilus influenzae (NTHi) Infection and Airway Inflammation in COPD. PLoS One. 2016; 11(11):e0167250. PMC: 5127575. DOI: 10.1371/journal.pone.0167250. View

3.
Segal L, Martinez F . Chronic obstructive pulmonary disease subpopulations and phenotyping. J Allergy Clin Immunol. 2018; 141(6):1961-1971. PMC: 5996762. DOI: 10.1016/j.jaci.2018.02.035. View

4.
Millares L, Ferrari R, Gallego M, Garcia-Nunez M, Perez-Brocal V, Espasa M . Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2014; 33(7):1101-11. PMC: 4042013. DOI: 10.1007/s10096-013-2044-0. View

5.
Kim V, Coombs N, Staples K, Ostridge K, Williams N, Wootton S . Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. Eur Respir J. 2017; 50(4). DOI: 10.1183/13993003.00853-2017. View